Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMA2 in Hyperuricemia Associated With Gout
NCT07889284Phase 3Not yet recruiting
- Sponsor
- ScandiBio Therapeutics
- Start
- Oct 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gout and hyperuricemia (2 arms), sponsored by ScandiBio Therapeutics. Primary endpoint: Serum Uric Acid Levels at 4 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT07889284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07889284.